

Subject Index

a

AB₅ toxins, multivalency with 581–586
 5-acetamido-3,5-dideoxy-D-glycero-D-galacto-
 non-2-ulopyranosonic acid 55
 N-acetyl-D-glucosamine 863
N-acetylgalactosaminyltransferase 147
 – α -N-acetylgalactosaminyltransferase 640
 – β -N-acetylgalactosaminyltransferase
 620–625
N-acetylglucosamine kinase 146
N-acetylglucosamyltransferase 622–624
 – chitin β (1–4)*N*-acetylglucosamyltransferase
 (chitin synthetase) 624
 – *N*-acetylglucosamyltransferase V 622
N-acetylmannosamine 734
N-acetylneuraminic acid 61–62, 864
 – mimetics 840
 – synthesis via 2-chloro derivates 61
 acharan sulfate 425–430
 aclacinomycin A 689
 acridine 676
 – neo-acridine 676
N-acetylation 664
N-acyl 863–872
N-acyl-modified sialic acids 869–871
 Ada-Gb₃Cer 768–769, 776
 adamantyl-acyl ceramide 775–778
 Ada-ScCer 768
 S-adenosylmethionine 731
 Ag salt, insoluble (silver silicate) 261
 aglycon delivery, intramolecular 269
 C-aglyconic bonds 316
 D-Ala-D-Ala 912
 alginates 428
 altromycin B 689
 amicetin 695
 amino-bonded silica 528
 4-amino-4-deoxy-Neu5Ac2en 837
 6-aminodeoxy-Ada-Gb₃Cer 770

aminoglycoside-arginine conjugates 677
 aminoglycoside-intercalator
 conjugates 675–676
 antibiotics 694–695, 909–912
 – aminoglycoside 664–666
 – macrolide 913–917
 aminoglycosides 484, 694, 917–922
 – antibiotics, aminoglycoside 664–666
 – dimeric 673–675
 – guanidinoglycoside 677–679
 – heterocyclic 2-deoxystreptamine aminogly-
 coside analogues, interaction with
 RNAs 483–498
 – RNA-aminoglycoside (*see there*) 497,
 661–680, 694
 – – aminoglycosides as RNA-binders
 666–670
 aminosugars, biosynthesis 725–730
 angiogenesis
 – heparin 414
 – tumor angiogenesis 808–809
 angucycline 701
 anion exchange 528–529
 anthrachinone glycoside 703–704
 anthracycline 689
 anti-adhesives, multivalency in 587–595
 antiatherosclerotic activity, heparin 412–413
 antibodies
 – anti-sialyl Le^x antibody 804, 813
 – IgG 204
 – monoclonal antibodies (*see there*) 809–812
 antigens
 – carbohydrate-based 382
 – T antigen 179, 186, 204
 anti-infective disease, heparin 415
 anti-inflammatory activity, heparin 413–414
 anti-influenza agents (*see also* influenza)
 831–856

- antithrombin 444, 449, 453–454
 antithrombotics 441–457
 – factor Xa 442–444, 446, 449–450, 454–455
 – heparin (*see there*) 411–412, 442–446
 – pentasaccharides (*see there*) 446–451
 – thrombin inhibition 452–455
 armed and disarmed 6
 asparagine (Asn)-linked
 – Asn-Xaa-Ser /Thr /Asn-Xaa-Thr / Ser sequences 282, 288
 – glycoprotein oligosaccharides, chemical synthesis 253–278
 – protein glycosylation 281–301
 aspartic acid, Fmoc /tBu-protected aspartic acid 174
 aureolic acid 690–692
 automation 29–32
 auxiliaries 74
 – 3-seleno auxiliaries 74–77
 – 3-thio auxiliaries 74–77
 avermectin 701
 avidities 562
 avilamycin C 217
 2-azidogalactosyl threonine 180
- b**
- B cell 209
 bacterial
 – adhesion 587–592
 – chemoattractants, multivalent 600–602
 – GlcNAc-6-ST 785
 – infection 899–927
 – lyase 523
 – polysaccharide vaccines 397–401
 – – synthetic parasitic polysaccharide conjugate vaccine 402–403
 benzoisochromanequinone 701
 N-benzoyl-Dab-Leu-Thr-NHMe 289
 binding isotherm 542–544
 bioactive glycosylated secondary metabolites 686–707
 bisubstrate analogues inhibitor 648–653
 bleomycin 688
 block synthesis 8–11
 blood, human blood group trisaccharides 334–336
 $n\text{Bu}_3\text{SnH}/\text{AIBN}$ 244
 N-butyl-1-deoxynojirimycin (NB-DN) 611
- c**
- C*'-anti-*C'* conformer 305, 311
C'-anti-*C3'* conformer 317, 320, 323
C'-anti-*C5'* conformer 323
C'-anti-*H'* conformer 311
C'-anti-*O'* conformer 311
C1'-anti-*C1'* conformer 326
C1'-anti-*C3'* conformer 326
 C-aglyconic bonds 316
 calicheamicin 686
 cancer (*see also tumor*)
 – angiogenesis 808–809
 – breast cancer 805
 – colon cancer 805
 – gastric cancer 805
 – heparin and cancer 414–415
 – lung cancer 805
 – metastasis (*see there*) 803–824
 – prostate cancer 805
 – vaccines 382–397
 capillary electrophoresis (CE) 530
 cap-tags 123
 carafate® (sucralfate) 429
 carbohydrate synthesis, complex 37–52
 – antigens, carbohydrate-based 382
 – cell-surface carbohydrates 900–904
 – everninomicin 13,384-1 215–250
 – FACE (fluorophore-assisted carbohydrate electrophoresis) 530
 – gangliosides, synthetic (*see there*) 38–51
 – multivalent carbohydrate ligands (*see there*) 575–605
 – polymer-supported synthesis 129–136
 – toxin receptor 50–52
 – vaccines, synthetic carbohydrate-based 381–403
 – – bacterial polysaccharide vaccines 397–401
 – – cancer vaccines 382–397
 carbon-carbon *gauche* interaction 311
 CarboPac PA1 529
 cardiac glycosides 702–703
 cartilage proteoglycans, keratan sulfate 424
 castanospermine 300
 C-celllobiose 316
 CD4⁺ T-cell epitope 396
 C-disaccharide 308, 314
 CDP-3,6-dideoxy-D-glycero-D-glycero-4-hexulose 717
 CDP-[4-²H]paratose 737–738
 CDP-D-glucose 4,6-dehydratase 715
 CDP-D-[2-²H]paratose 737–738
 CDP-tyvelose 2-epimerase 735–737
 cell-aggregation, multivalent ligand-mediated 602
 celllobiose
 – C-celllobiose 316

- *C2-epi-C*-cellobiose 319
 - cell-surface carbohydrates 900–904
 - ceramide β -glucosyltransferases 611–615
 - ceramide-cholesterol composition 775
 - ceramide-subtype composition, glycolipid mimics 762–764
 - heat shock protein Hsp70 to sulfogalactosyl ceramide 772–775
 - C*-glycosides 305–337, 312–313, 334, 336
 - chelate effect 576
 - chemiluminescence 526
 - chemokines 416
 - chitins
 - chitin $\beta(1\rightarrow 4)$ *N*-acetylglucosamyltransferase (chitin synthetase) 624
 - sulfated chitins 427
 - chitobiose 296
 - chitobiosylamine 296
 - chlorobiphenyl vancomycin 912
 - Chol-1 gangliosides 47, 49–50
 - GD1 α 47, 49
 - GD1 β 50
 - GQ1ba 10, 47, 49–50
 - GT1aa 47, 49
 - cholera toxin 584–586
 - chondrin 407
 - chondroitin sulfate (*see* dermatan and chondroitin sulfate) 407–408, 417–419, 518
 - chondroitinase 522
 - chromatography (*see* GC-MS) 462, 471, 527
 - circular topology 572
 - CK'TUF 159
 - cleavage
 - A-type cleavage 468
 - β -cleavage 468
 - Clostridium perfringens* 90
 - cluster effects 131, 576–577
 - C*-monoglycoside 309–313
 - CMP
 - CMP 3-fluoroneuraminic acid 87
 - CMP Neu5Ac (*see also* Neu5Ac) 85
 - regeneration 149
 - synthetase 150
 - coagulation factor 442
 - C*-oligosaccharide 336
 - complement activation, heparin 413
 - complex carbohydrate synthesis (*see* carbohydrate) 37–52, 129–136, 215–250
 - concanavalin A (Con A) 578
 - conformer/conformation/conformational analysis 305
 - *C'-anti-C'* 305, 311
 - *C'-anti-C3'* 317, 320, 332
 - *C'-anti-C5'* 332
 - *C'-anti-H'* 311
 - *C'-anti-O'* 311
 - *C1'-anti-C1'* 326
 - *C1'-anti-C3'* 326
 - *exo/anti* 305, 310–311, 326, 332
 - *exo/gauche* 307
 - *exo/gauche C-anti-H* 333
 - *exo-anomeric* 306–310
 - *exo/anti* 310
 - *nonexo/gauche* 307
 - consensus sequence Asn-Xaa-Ser/Thr 282
 - controlled pore glass (CPG) 108
 - corneal proteoglycans, keratan sulfate 424
 - 2D COSY 532
 - coumarin 699–701
 - CPG (controlled pore glass) 108
 - CSLEX-1 810
 - C*-trisaccharide 324–325, 336
 - cyclohexane-1,2-diacetal 273
 - cytidine 5'-monophosphate kinase 150
- d**
- DAST 228
 - DBU 230, 245
 - DDP (dibenzyl-*N,N*-diethylphosphoroamide) 71
 - DDQ 228, 240, 247
 - DEFGHA₂ 245–247
 - dendigraft 592
 - dendrimer 396–397, 592
 - C-2-deoxygenation 721
 - C-4-deoxygenation 723–725
 - 3-deoxy-D-glycero-D-galacto-non-2-ulopyranosonic acid 55, 57
 - synthesis 57–58
 - 2-deoxy- β -glycoside 223
 - 4-deoxy-4-guanidino-Neu5Ac2en 839, 844, 846–847
 - derivates 841
 - C-7-substituted 847
 - 1-deoxymannojirimycin 300
 - 4-deoxy-Neu5Ac2en 841
 - 1-deoxynojirimycin 300
 - 2-deoxystreptamine (2-DOS) 483–499, 664, 920
 - 2-DOS aminoglycoside analogues, heterocyclic, interaction with RNAs 483–498
 - imidazolyl 2-DOS derivates 493
 - 4-substituted 2-DOS derivates 491–493
 - deoxysugars, biosynthesis 714–725
 - dermatan and chondroitin sulfate 407–408, 417–419, 518

- structure and biological role 417–418
 - therapeutic applications 418–419
 - desoxamine 722–725, 915
 - Dess-Martin* periodinane 239
 - dextran sulfate 427–428
 - DHPE (1,2-dihexadecyl-*sn*-glycero-3-phosphoethanolamine) 750
 - N,N*-dialkylated 4-amino-4-deoxy-Neu5Ac2en 841
 - 1,3-diaxial-like steric interactions 320, 323
 - diazobenzofluorene 689
 - dibenzyl-*N,N*-diethylphosphoroamidite (DDP) 71
 - dibutylboron triflate 3
 - 2,6-dideoxy-L-sugar 225
 - diethyl β -sialyl phosphites 71
 - 2-(diethyl)phosphite 71
 - digitoxin 702
 - dihedral angles ϕ and φ 305
 - 1,2-dihexadecyl-*sn*-glycero-3-phosphoethanolamine (DHPE) 750
 - dimer
 - (2→8)-linked dimer 78
 - (2→8)-linked sialyl dimer 73
 - Neu5Aca (2→8) Neu5Ac dimer 81
 - P^k-dimer 559
 - dimeric aminoglycosides 673–675
 - dimethyl(methylthio)sulfonium trifluoromethanesulfonate (*see* DMTST) 62–63
 - N,N*-dimethylglycolamido (OCH₂CONMe₂) 67
 - Dionex CarboPac PA100 507
 - disaccharide
 - 1,1'-disaccharide 220, 235, 249
 - bridge 231
 - C-disaccharide 308, 314
 - disarmed, armed and disarmed 6
 - DMTST (dimethyl(methylthio)sulfonium trifluoromethanesulfonate) 62–63
 - DMTST-promoted
 - glycosylation 68
 - sialylation 63
 - DNA
 - B-DNA-type minor groove 686
 - glycosylated agents that interact with DNA 686–692
 - substrate competition with A- and B-transferases and DNA methylation 822–823
 - dolichol phosphate 170
 - Dol-PP-GlcNAc-Glc 293
 - domains 452–454
 - A-domain 452
 - introduction of a neutral domain 454–455
 - T-domain 452–455
 - DPPE (dipalmitoyl phosphatidylethanolamine) 749
- e**
- E5531 350, 352
 - E5564 350–352
 - EI (electron impact) 462–463
 - A-type cleavage 468
 - β -cleavage 468
 - β -elimination 172, 468, 524–525
 - Endo*- β -N-acetylglucosaminidase 182
 - endotoxin 342
 - antagonists 353
 - enediyynes 686–688
 - enthalpic effect 564
 - enzymes
 - enzymatic mechanism in the biosynthesis of unusual sugars (*see also* sugar) 713–741
 - fragment condensation, enzyme-catalyzed 198
 - GAGs, enzymes that degrade GAGs 521
 - 4-*epi*-amino-4-deoxy-Neu5Ac2en 842
 - C-2 epimerization 735
 - epi*-vancosamine 912
 - 1,2-epoxide 25
 - erythromycin A 694
 - ES/ESI (electrospray ionization)-MS 464, 484–485, 533–535
 - ES-MS/MS 473
 - NanoES 464
 - Escherichia coli* (*E. coli*)
 - bundle's decavalent ligand for the *E. coli* Shiga-like toxin 582–583
 - *E. coli* heat-labile enterotoxin 584–586
 - EST inhibitors/inhibition
 - bisubstrate analogue approach to EST inhibition 788–789
 - discovery of EST inhibitors from a library of PAP analogues 789–790
 - inhibition of EST by dietary agents and environmental toxins 791–792
 - inhibitors of EST targeted toward the PAPS binding site 784–786
 - everninomicin
 - everninomicin 13,384-1 215–250
 - everninomicin B 217
 - exo/anti* conformation 305, 310–311, 326, 332
 - exo/gauche* C-anti-H conformation 333

- exo/gauche* conformation 307
- exo- β -galactosidase 477
- exo-anomeric conformation 306–310

f

- FAB (fast atom bombardment)-MS 462–463, 467, 471, 473
 - of deuteroreduced permethylated HSP sample 473
- FACE (fluorophore-assisted carbohydrate electrophoresis) 530
- factor Xa 442–444, 446, 449–450, 454–455
- fluorescent tagging 526
- 5-fluoroac-Neu 868
- fluorophore tagging 461
- Fourier transformation ion cyclotron resonance (FT-ICR)*-MS 466, 484
- French paradox 707
- FT-ICR (*Fourier transformation ion cyclotron resonance*)-MS 466, 484
- fucoidins 426–427
- fucosyltransferase (Fuc-T) 148, 816–818
 - Fuc-T VII 818
 - Fuc-Ta 625–632
 - Fuc-Ta(1–3) 650
- functional affinity 575

g

- GAG (glycosaminoglycans) 407–432, 517–537, 885
 - acharan sulfate 425–430
 - alginates 428
 - analytical tools used in the structural characterization of GAGs 527–536
 - biological activities 408–416
 - chondroitinase 522
 - degrade GAG oligosaccharides 521–524
 - – chemical methods 524
 - – enzymes that degrade GAGs 521
 - depolymerization of nascent GAG chains 521–524
 - dermatan and chondroitin sulfate (*see there*) 407–408, 417–419, 518
 - detection of GAG oligosaccharides 525–527
 - dextran sulfate 427–428
 - fucoidins 426–427
 - heparin and heparan sulfate [HSGAGs] (*see there*) 407, 409–416, 442–446, 518, 529, 535, 755
 - heparinase 522
 - hyaluronan/hyaluronic acid (*see there*) 407, 419–423
 - IP-RPHPLC 529

- keratan sulfate (*see there*) 407–408, 423–425, 517–518
- linear complex polysaccharides 517–521
- lyase 525
- pharmaceutical potential and challenges 430
- sulfated chitins 427
- α -Gal oligosaccharides 158
- Gal-1-P uridyltransferase 142
- galactofuranose 738
- galactosidase, exo- β -galactosidase 477
- galactosyl ceramide (GalCer) 766
- α -galactosyltransferase 637–640
 - α (1–3) 637–638
 - β -galactosyltransferase 616–620
 - β (1–4) 637
- GalCer (galactosyl ceramide) 766
- gangliosides, synthetic 38–50–51
 - Chol-1 47, 49–50
 - GD1a 47, 49
 - GD1 β 50
 - GM1 50, 391
 - GM3 38
 - GM4 38
 - GQ1ba 10, 47, 49–50
 - GT1aa 47, 49
 - GT1b 50–51
 - L-selectin (*see selectin ligands*) 41, 43–46
 - sialylparagloboside (SPC) 40
 - siglec ligands (*see there*) 46–50
 - sulfated gangliosides 50
- gangliotriacylceramide 762
- gated decoupling ^{13}C NMR 23
- gauche carbon-carbon interaction 311
- Gb₃Cer 763–764
- Gb₃P^k 764
- GC (chromatography)-MS 462, 471
 - HPLC (high pressure liquid chromatography) 527–529
 - sugar analysis 471
- GCMP 359–362
- immunology 362–363
- GD1a 47, 49
- GD1 β 50
- GD3-KLH 391
- GDP-2-fluoro-fucose 627
- GDP-Fuc 147–148
 - regeneration 148
- GDP-mannose (GDP-Man) 147–148
 - pyrophosphorylase 148
 - regeneration 148
- gel electrophoresis, polyacrylamide 530
- gel-permeation, high-performance 528

- gentamycin 664
 ginsenoside 704
 GlcNAc thiazoline 298
 GlcNAc-6-O-STs 785
 GlcNAc-6-ST, bacterial 785
 glial cells, stimulation of 869–870
 Globo-H 388–390, 923
 Globo-H-KLH 389
 globotriaose 770
 α -D-glucopyranosyl phosphate thymidyltransferase 917
 D-glucuronic acid 407, 448
 glucosamine-6-phosphate, biosynthesis 727–729
 – synthetase 727–729
 glucosamine-6-O sulfatase 523
 glucosinolate 705
 UDP-glucuronic acid 633
 β -glucuronosyltransferase 632–636
 glycals 4, 24–25, 267–269
 – assembly approach 112–113
 – method 25
 glycan, sequencing and structural determination 470–475
 – glycan derivatization 471–472
 – O-glycan (*O*-mannosyl), brain 754
 O-glycanase 508
 glycoalkaloids 704–705
 glycolipids 763
 – glycolipid mimics, membrane-presented 761–776
 – ceramide subtype composition (*see there*) 762–764, 772–775
 – lipid replacement structural motifs (LRSMs) 766–768
 – verotoxins 764–766
 N-glycolyneuraminic acid (Neu5Gc) 94
 glycome 747
 – mammalian glycomics 475–477
 glycopeptides
 – HYCRON-linked 194
 – MUC1 394
 – PSGL-1 187
 – solid-phase synthesis of *N*-glycopeptides 188–191
 – synthetic chemistry and biology 169–209
 – thioesters 199
 glycoprotein 281
 – asparagine-linked glycoprotein oligosaccharides, chemical synthesis 253–278
 – processing 287–288
 – sequencing 461–481
 – synthetic chemistry and biology 169–209
- glycorandomization 917
 glycosaminoglycan (*see GAG*) 407–432, 517–537, 885
 glycosidase 138
 glycosidase-catalyzed transglycosylations 137
 glycosidation
 – phospholipids, glycosidated 875–881
 – sulfur-directed 224
 – trichloroacetimidate-mediated 218
 glycoside-based substrates 883–884
 glycosides/glycosidic
 – anthrachinone glycoside 703–704
 – C-glycosides 305–337, 312–313, 334, 336
 – C-monoglycoside 309–313
 – cardiac glycosides 702–703
 – 2-deoxy- β -glycoside 223
 – glycoside primers 883–892
 – xylosides 884–885
 – linkage 169–171
 – α (2→8)/ α (2→9) 77
 – as metabolic decoys 888–889
 – Neu5Ac, C-glycosides 92
 – O-glycosides 305–337
 – n-pentenyl 9, 118, 265–267
 – 2-phenylsulfonamido-thioglycoside 26
 – phenylthioglycosides 3, 218
 – plant polymeric natural glycoside 707
 – selenoglycoside 225
 – selenyl 6
 – sialic acid, C- und S-glycosides 91–94
 – thioglycosides (*see there*) 6, 110, 115–117, 233
 – 2-thiophenyl 67
 – triterpenoid glycoside 707
 glycosyl
 – acceptors 105–106
 – azide 173
 – bromide 229
 – donors 105–106
 – 2-phosphites, as glycosyl donors 71
 – 2-xanthates, as glycosyl donors 69–71
 – fluoride 4, 8, 118, 218, 220, 226, 229, 247
 – phenylsulfoxide 218
 – phosphates 118, 121
 – sulfoxides 113
 – transfer, mechanism for 294–296
 – trichloroacetimidate 3, 114–115, 121
 glycosylation
 – asparagine (Asn)-linked protein glycosylation 281–301
 – DMTST-promoted 68
 – N-linked 287

- rPSGL-Ig 515
- natural products, glycosylated (*see there*) 685–707
- NMP-sugar donors 641–648
- one-pot sequential 14
- sialic acid, chemical glycosylation 59–83
- glycosyltransferase/glucosyltransferase inhibitors 83, 88, 609–654, 714
- bisubstrate analogues inhibitor 648–653
- β -glucosyltransferases 611–615
- ceramide 611–615
- T4 614
- immobilized 152–153
- inverting 610–636
- Leloir 138
- NDP-sugar donors 610–640
- NMP-sugar donors 641–648
- non-Leloir 138
- retaining glycosyltransferase 636–640
- use in solid-phase synthesis 88
- glycosynthase 138
- glycosynthesis, automated 130
- GM1 50
 - fucosyl 391
- GM2-KLH conjugate 384
- GM3 38
- GM3Cer 775
- GM4 38
- Golgi-resident sulfotransferases (GSTs) 792–794
- gp120 775–776
- GPI anchor 402
- GQ1 β 10, 47, 49–50
- growth factors 416
 - vascular endothelial growth factor (VEGF) 814
- GSTs (Golgi-resident sulfotransferases) 792–794
- GT1aa 47, 49
- GT1b 50
- guanidine-neomycin B 678
- 4-guanidino *N,N*-di-(*n*-propyl)carboxamide 851
- guanidinoglycoside 677–679
- h***
- haemagglutinin (HA) 592, 832–833
- heat shock protein Hsp70 to sulfogalactosyl ceramide 772–775
- heat-labile enterotoxin, *E. coli* 584–586
- hedamycin 689
- helper T cell 206
- Hep (L-glycero-D-manno-heptose) 900
- heparin and heparan sulfate (HSGAGs)
 - glycosaminoglycans 407, 409–416, 442–446, 518, 529, 535, 755
 - angiogenesis 414
 - antiatherosclerotic activity 412–413
 - antiinfective disease 415
 - antiinflammatory activity 413–414
 - antithrombotic activity 411–412
 - applications 411–416
 - biosynthesis and biological functions 410–411
 - complement activation 413
 - heparin and cancer 414–415
 - interactions with proteins 415–416
 - limitations 445–446
 - tetrasaccharide sequence on heparan sulfate 755
- heparinase 522
- heparin-induced thrombocytopenia (HIT) 441
- HMQC 27
- HPAEC/PED 502–509
- HPLC (high pressure liquid chromatography) 527–529
- HR-MAS 27
- HSGAGs (*see* heparin and heparan sulfate) 407, 409–416, 442–446, 518, 529, 535, 755
- HSP (human seminal plasma) 470
 - FAB-MS of deuteroreduced permethylated HSP sample 473
 - HSP70 (heat shock protein) to sulfogalactosyl ceramide 772–775
- 2D HSQC 532
- human
 - blood group trisaccharides 334–336
 - seminal plasma (*see* HSP) 470, 473
- hyaluronan/hyaluronic acid (HA) 144, 407, 419–423
 - functions and applications 421–423
 - structure and properties 419–420
 - tissue distribution and biosynthesis 420–421
- hyaluronidase 423, 525
- HYCRON-linker 192
 - glycopeptide, HYCRON-linked 194
- 1,3-hydroxamine 668
- hydroxselenide 238
- i***
- L-iduronic acid 407, 446
- iduronidase 523
- IgG 204

- antibodies 206
- isotype 364
- IgM 204
- imidazolyl 2-deoxystreptamine
 - derivates 493
- immune response 595–596
- immunotherapy 383
- indolocarbazole 699
- infection, bacterial 899–927
- influenza virus 592–595
 - anti-influenza agents 831–856
 - influenza A 834, 867
 - influenza B 854
 - virus sialidase 834–855
- integrin-ICAM-1 809
- integrin-mediated ligation 183
- intercalators 675–676
- inverting glycosyltransferases 610–636
- 9-iodo-NeuAc 868
- IP-RPHPLC 529
- isotherm 542–546
 - binding 542–544
 - competitive inhibition 544–546
- j**
- josamycin 694
- k**
- kanamycin 664
 - 3'-oxo derivate 921
- Karplus equation 309
- KDN (2-keto-3-deoxy-D-glycero-D-galacto-nononic acid) 372
- KDO (3-deoxy-D-manno-octulosonic acid) 57, 900
 - L-KDO 903
- KDO-8-phosphate 900
- keratan sulfate 407–408, 423–425, 517–518
 - biological role 425
 - cartilage proteoglycans 424
 - chemistry and biosynthesis of linkage regions 424
 - corneal
 - molecular corneal dystrophy 425
 - proteoglycans 424
 - structure and distribution 423–424
- 2-keto-3-deoxy-D-glycero-D-galacto-nononic acid (KDN) 372
- ketolides 915
- keyhole limpet hemocyanin (*see* KLH) 384–386
- KLH (keyhole limpet hemocyanin) 384–386
 - GD3-KLH 391
 - Globo-H-KLH 389
 - GM2-KLH conjugate 384
 - Le^Y-KLH 391
 - MUC1-KLH 391
 - MUC2-KLH 391
 - STn(c)-MBS-KLH 386
- I**
- C-lactose 305
 - C-lactose vs. O-lactose 331–333
- lactosylceramide 763
- LC-MS 464
- Leloir glycosyltransferase 138
- Leloir pathway 83
- leukemic cells, multiple organ infiltration of 806–807
- N-levulinoylmannosamine 90
- Lewis
 - Lewis Y (Le^Y) 186, 386–387
 - Le^Y-KLH 391
 - sialyl Lewis^a (*see there*) 816–822
 - sialyl Lewis^x (*see there*) 23, 41, 44–46, 67, 88, 181, 188, 503
 - sulfo Lewis^a (sulfo-Le³) sequences 753
 - sulfo Lewis^x (sulfo-Le^x) 23, 41, 44–46, 67, 753
- ligation, native chemical 199
- lignan 703
- linkage
 - $\alpha(2\rightarrow8)$ -linkage 83
 - glycosidic 169–171
 - β -mannose linkage 173
 - β -mannoside linkage 241, 276
- link/linked
 - (2→8)-linked 73, 77–83
 - - dimer 78
 - - sialosides 77–83
 - - sialyl dimer 73
 - (2→9)-linked 73
 - N-linked glycosylation 287
- linkers
 - acid-labile 109–110
 - base-labile 109–110
 - HYCRON-linker 192
 - olefin metathesis 111–112
 - photocleavable 111
 - PTMSEL 195
 - to the support 20
 - thioglycoside 110
- lipids
 - lipid II 907, 910
 - lipid X 343, 346
 - - analogues 343

- lipid A 341–353, 901
 - antagonist for sepsis treatment 341–353
 - first generation 344–348
 - second generation 348–351
 - lipid carriers 392–394
 - lipid replacement structural motifs (LRSMs) 766–768
 - sphingoglycolipid 133
 - lipopolysaccharide (LPS) 341, 346–348, 352, 400–401, 815
 - $\text{Li}(\text{BuO})_3\text{AlH}$ 239
 - L-KDO 903
 - LPS (lipopolysaccharide) 341, 346–348, 352, 400–401, 815
 - LRSMs (lipid replacement structural motifs) 766–768
 - lung carcinoma, small cell (SCLC) 391
 - 2,6-lutidine 243, 247
 - lymph node infiltration mediated by L-selectin 807
 - T-lymphocytes by ManProp 869
 - lysosomal hydrolase 523
- m**
- macrolide 692–694
 - antibiotics 913–917
 - MAdCAM-1 peptide 192
 - MALDI (matrix-assisted laser desorption ionization) 462–469, 506, 533–536
 - MALDI-MS 462–463
 - MALDI time of flight (MALDI TOF)-MS 27, 536
 - MALDI-Q-TOF 466, 469, 506
 - β -mannopyranosides 13
 - mannose
 - β -mannose linkage 173
 - GDP-mannose pyrophosphorylase 148
 - PMI (phosphomannose isomerase) 147
 - β -mannoside linkage 241, 276
 - β -mannosidase 222
 - mass spectrometry (MS) 462–466, 471, 533–536
 - chromatography (*see* GC-MS) 462, 471, 527
 - EI (electron impact) 462–463
 - ES/ESI (electrospray ionization)-MS (*see there*) 464, 473, 484–485, 533–535
 - FAB (fast atom bombardment)-MS 462–463, 466, 469, 473
 - FT-ICR (*Fourier* transformation ion cyclotron resonance)-MS 466, 484
 - LC-MS 464

- MALDI (matrix-assisted laser desorption ionization)-MS (*see there*) 27, 462–463, 466, 469, 506, 533–536
- MS-based sequencing strategies 466–470
- MS/MS and mass analyzers 465–466, 487, 535
- neoglycolipids 750–752
- $(\text{Me}_2\text{N})_2\text{CF}^+\text{PF}_6^-$ 227
- meningitis 357
- meningococcal vaccines 358–371
 - group B 362–365, 366–371
 - group C 358–362
- mercaptoethylsulfonic acid 183
- Merrifield* resin 104
- Merrifield*-type polystyrene (PS) 19
- metabolic
 - decoys 888–889
 - labeling 526–527
- metastasis, carbohydrate-based treatment 803–824
 - breast cancer 805
 - use of carbohydrate derivates 812–814
 - chemoprophylaxis of cancer metastasis 815–816
 - colon cancer 805
 - distant hematogenous metastasis of cancer cells 803–806
 - diversity of selectin ligand expression on cancer cells 809–812
 - gastric cancer 805
 - lung cancer 805
 - lymph node infiltration mediated by L-selectin 807
 - use of monoclonal antibodies for inhibition of cancer cell-endothelial interaction 809–812
 - multiple organ infiltration of leukemic cells 806–807
 - other carbohydrate determinants involved in distant metastasis 807
 - prostate cancer 805
 - regulation of selectin expression on endothelial cells 814–816
 - substrate competition with A- and B-transfases and DNA methylation 822–823
 - sialyl Le^α and sialyl Le^β expression in cancer 816, 823–824
 - tumor angiogenesis 808–809
- p*-methoxybenzyl (PMB) 110
- p*-methylbenzoyl 15
- p*-methylbenzyl 15
- methymycin / pikromycin 722

- MHC 206–207
 – class I 206–207
 – class I-peptide 206
 – class II 206–207
 – class II-peptide 206
 microbial α 2 \rightarrow 3 sialyltransferase 186
 midecamycin 694
 mithramycin 690
 MKN74 cells 810
 monomycin 909
 monitoring of reaction progress 26–29
 monoclonal antibodies for inhibition of cancer cell-endothelial interaction 809–812
C-monoglycoside 309–313
 monovalent ligand vs. multivalent receptor 546–550
 MPEG (polyethyleneglycol monomethyl ether) 11–12
 MraY 904
 MUC2 21, 192
 – mucin MUC2 protein 21
 MUC3 192
 MUC1 glycopeptide 394
 MUC1-KLH 391
 MUC2-KLH 391
 multivalent/multivalency
 – AB₅ toxins, multivalency with 581–586
 – anti-adhesives 587–595
 – bacterial chemoattractants 600–602
 – carbohydrate ligands 575–605
 – cell-aggregation, ligand-mediated 602–603
 – chelate effect 576
 – clustering effect 576–577
 – as effectors 596–604
 – functional affinity 575
 – as inhibitors of immune response 595–596
 – mechanisms of binding of 576–577
 – selectins (*see there*) 603–604
 – statistical effect 577
 – effect, multivalency 564
 – thermodynamic models of multivalency effect 541–573
 – interaction 562–570
 – receptor
 – multivalent receptor vs. monovalent ligand 546–550
 – multivalent receptor vs. multivalent ligand 551–552
 – *Shiga*-like toxin
 – bundle's decavalent ligand for the *E. coli* *Shiga*-like toxin 582–583
 – radially arranged multivalent ligands for 565–570
 – systems 553–555
 – topological classification 553–555
 mycaminoose, biosynthesis 729–730
 mycarose 732–733
- n**
- 2-naphthalenethiol β -D-xyloside 884
 native chemical ligation 199
 natural products, glycosylated agents that interact 685–707
 – with cell walls and cell membranes 695–699
 – with DNA 686–692
 – with other (or undefined) targets 706–707
 – with proteins 699–705
 – with RNA 692–695
 NDP-glucose 4,6-dehydratase 715
 NDP-4-keto-6-deoxyglucose 716
 NDP-sugar donors 610–640
Neisseria gonorrhoeae, sialyltransferase 86
 neo-acridine 676
 neoglycolipids 747–757
 – first generation 749
 – mass spectrometry 750–752
 – scope of the neoglycolipid technology 752
 neomycin 489–490, 494, 664
 – guanidine-neomycin B 678
 – isolation of sugar ring fragments from neomycin 494
 – neomycin B 918
 – and TAR RNA 489–490
 Neu5Ac
 – aldolase 56, 59
 – C-glycosides 92
 – CMP Neu5Ac 85
 – analogues 85
 – synthase 85
 Neu5Ac2en (2-deoxy-2,3-didehydro-N-acetylneuraminic acid) 836, 855
 – 4-amino-4-deoxy-Neu5Ac2en 837
 – 4-deoxy-4-guanidino-Neu5Ac2en (*see there*) 839, 844, 846–847
 – 4-deoxy-Neu5Ac2en 841
 – *N,N*-dialkylated 4-amino-4-deoxy-Neu5Ac2en 841
 – 4-*epi*-amino-4-deoxy-Neu5Ac2en 842
 Neu5Aca (2 \rightarrow 8) Neu5Ac
 – dimer 81
 – moiety 83
 Neu5Gc (*N*-glycolylneuraminic acid) 94

IV³NeuAca, III³FucanLc⁴Cer 133
 (NeuNPSA)₄-TT 368
 neurons, stimulation of 870–871
 nikkomycin Z 625
 NIS/TfOH 63
 nitrous acid 524
 NK cells 806
 NMP-sugar donors 641–648
 NMR spectroscopy 23, 327, 532–533
 – 2D-NOESY 327
 – gated decoupling ¹³C NMR 23
 NodH 786
 NOESY studies 316
 – 2D-NOESY NMR spectroscopy 327
nونexو/gauche conformation 307
 non-lelior glycosyltransferase 138
 non-ribosomal peptide 695–697
 NPr PSA 370, 373
 nucleotidyldiphospho-4-hexulose 714

o

OCH₂CONMe₂ (*N,N*-dimethylglycolamido) 67
 O-glycosides 305–337
 oleandomycin 694
 olefin metathesis, linkers cleaved by 111–112
 oligosaccharide synthesis 1–3, 103–125
 – arrays / microarrays 755–757
 – asparagine-linked glycoprotein oligosaccharides, chemical synthesis 253–278
 – C-oligosaccharide 336
 – enzymatic synthesis 137–162
 – – cell-free 151–156
 – – large-scale synthesis with whole cells 156–161
 – – whole cell-based technologies 161
 – *a*-Gal oligosaccharides 158
 – *N*-linked oligosaccharide 507–508, 515
 – *O*-linked oligosaccharide 511
 – programmable 31
 – – one-pot oligosaccharide synthesis 922–927
 – sequencing 461–481
 – solid-phase 16, 20–21, 103–125
 – – automated 118–120, 123
 – – bi-directional strategy 107
 – – synthetic strategies 105
 oligosaccharide-binding proteins 748
 oligosaccharyl transferase 281–301
 olivomycin A 690
 O-mannosyl, brain 754
 OptiMer 923

orthogonal
 – protection 4
 – reactivities 7
 orthosomycin 692
 oxazoline 177

p

PAGE methods 530
 Pam₃Cys 394
 PAP-analogues 789–790
 PAPs 784, 792
 – binding site 784
 – – inhibitors of EST targeted 784–786
 paramomycin 486, 495–497, 664
 pathway engineering 156
 PBPs (penicillin binding proteins) 907
 PED (pulsed electrochemical detection) 501–516
 – HPACE / PED 502–509
 PEGA (poly(ethylene glycol)-polyacrylamide copolymer) 89
 penicillin binding proteins (PBPs) 907
 pentane-*syn* interactions 314
 pentasaccharides, antithrombotic 446–451
n-pentenyl glycoside 9, 118, 265–267
 PEP (phosphoenol pyruvate) 143, 150
 peptidoglycan 904–913
 (Ph₃P)₃RhCl / DAB-CO 236
 1,2-phenylseleno migration 249
 2-phenylseleno-1-fluoro donor 244
 2-phenylselenoglycosyl fluoride 234–235, 237
 1,2-phenylsulfeno migration 224
 2-phenylsulfonamido-thioglycoside 26
 phenylsulfoxide, glycosyl 218
 phenylthioglycosides 3, 218
 phosphatidylethanolamine, dipalmitoyl (DPPE) 749
 phosphites
 – 2-(diethyl)phosphite 71
 – diethyl β -sialyl phosphites 71
 – 2-phosphites, as glycosyl donors 71
 phosphoenol pyruvate (PEP) 143, 150
 phospholipids, glycosidated 875–881
 phosphomannose isomerase (PMI) 147
 O-phosphorylation 664
Photobacterium damsela 86
 PhSeH 230
 PhSX-type 75
 plant phenolics 707
 plasmon, surface plasmon resonance 132
 pLDR20-*a*KTUF 158
 pluramycin 689–690

- PMB (*p*-methoxybenzyl) 110
 PMI (phosphomannose isomerase) 147
 PNGase 515
 poly(ethyleneglycol)-polyacrylamide copolymer (PEGA) 89
 polyene 697–699
 polyethyleneglycol (PEG) 11–12, 19
 – monomethyl ether (MPEG) 11–12
 polyketide 703–704, 915
 polymers
 – high-performance 130
 – water-soluble 136
 polymer-supported synthesis of carbohydrates 129–136
 polioxin D 625
 polyphosphate 155
 polysaccharide (PSA) 363–375
 – acidic 425–430
 – extended helical epitope of PSA 364–365
 – GAG complex polysaccharides 517–521
 – on human cells 371–373
 – lipopolysaccharide (LPS) 341, 346–348, 352, 400–401, 815
 – NPr PSA 370, 373
 – vaccines, bacterial polysaccharide (*see there*) 397–401, 402–403
 B-polysaccharide-protein conjugates 363–364
 polysialic acids 56, 357–375
 polystyrene (PS) 16, 19
 – Merrifield-type 19
 – PS divinylbenzene, cross-linked 16
 PPA (pyrophosphatase) 145
 primers, water-soluble 131
 programmable oligosaccharide synthesis 31
 – one-pot oligosaccharide synthesis 922–927
 protease inhibitors (serpins) 416
 proteoglycans, keratan sulfate 424
 – cartilage proteoglycans 424
 – corneal proteoglycans 424
 PSA (see polysaccharide) 363–375
 PSGL-1 187, 503–504, 805
 – glycopeptide 187
 – rPSGL-Ig (*see there*) 503–504, 506, 510–511, 515
 PTMSEL linker 195
 pulsed electrochemical detection (*see PED*) 501–516
 pyridoxal 5'-phosphate (PLP) 718
 pyrophosphatase (PPA) 145
 pyrophosphorylase
 – UDP-Glc 142
 – UDP-GlcNAc 145
q
 QS-21 204, 384, 391–392
r
 radial topology 572
 ramnoplakin 697
 reaction progress, monitoring 26–29
 regeneration
 – of CMP-Neu5Ac 149
 – of GDP-Fuc 148
 – of GDP-Man 148
 – of sugar nucleotides 139
 – of UDP-GlcNAc 145–146
 retaining glycosyltransferase 636–640
 Rev-RRE binding 672
 Rho A 878
 ring-open metathesis polymerization (ROMP) 578–580, 601, 604
 RNA
 – as an emerging therapeutic target 661–663
 – glycosylated agents that interact with RNA 692–695
 – heterocyclic 2-deoxystreptamine aminoglycoside analogues, interaction with RNAs 483–498
 – identifying RNA targets and developing binding assays 670–673
 – neomycin and TAR RNA 489–490
 – RNA aptamers 666
 – RNA major groove 497
 – RNA polymerase II 201
 – rRNA (*see there*) 497
 – single-stranded RNA 662
 RNA-aminoglycoside 497, 694
 – aminoglycosides as RNA-binders 666–670
 – guanidinoglycoside 677–679
 – interactions 661–680
 RNA-ligand
 – A-site 486, 493
 – binding 486
 – recognition 661
 ROESY experiments 332
 ROMP (ring-open metathesis polymerization) 578–580, 601, 604
 rPSGL-Ig 503–504, 506, 510–511
 – N-glycosylation 515
 rRNA 497
 – 16S rRNA A-site 497

s

- saccharomicin 699
- SCLC (small cell lung carcinoma) 391
- selectin ligands
 - E-selectin 44, 804, 814–815
 - expression on cancer cells 809–812
 - L-selectin 41, 43–46, 416, 603–604, 807
 - lymph node infiltration mediated by L-selectin 807
 - shedding 604
 - multivalent ligands and the selectins 603–604
 - P-selectin 44, 416, 501–516
 - regulation of selectin expression on endothelial cells 814–816
 - sialyl *Lewis* (*see there*) 41, 44–46, 52, 67, 88, 181, 188
- selectin-mediated adhesion 803, 806
- selenium-assisted coupling 232
- 3-seleno auxiliaries 74–77
- 2-seleno-1-fluoro derivative 220
- selenoglycoside 225
- selenyl glycosides 6
- sepsis, lipid A antagonist for sepsis treatment 341–353
- sequencing of oligosaccharides and glycoproteins 461–481
 - chromatography (*see GC-MS*) 462, 471, 527
 - consensus sequence Asn-Xaa-Ser / Thr 282
 - FACE (fluorophore-assisted carbohydrate electrophoresis) 530
 - glycan, sequencing and structural determination 470–475
 - glycomics, mammalian 475–477
 - mass spectrometry (*see there*) 462–466, 471, 533–536
 - MS-based sequencing strategies 466–470
 - MS / MS and mass analyzers 465–466
 - NMR spectroscopy 23, 327, 532–533
 - PAGE methods 530
 - special case strategies 477–481
- Shiga*-like toxin
 - bundle's decavalent ligand for the *E. coli* *Shiga*-like toxin 582–583
 - P^k-trisaccharide ligands 557–561
 - radially arranged multivalent ligands for 565–570
- sialic acid 55–94
 - C- and S-glycosides 91–94
 - chemical glycosylation 59–83

- L-sialic acid 903
- N-acyl-modified sialic acids 869–871
- polysialic acids 56, 357–375
- sialidase 90–91, 832–834
- sialosides, (2→8)-linked 77–83
- sialyl
 - anti-sialyl Le^x antibody 813
 - diethyl β-sialyl phosphites 71
 - Le^a / sialyl *Lewis*^a 803, 816–822, 823
 - expression in cancer 816, 823–824
 - sialyl Le^a / sialyl Le^x, terminal structures 812
 - Le^x / sialyl *Lewis*^x 23, 41, 44–46, 52, 67, 88, 181, 188, 503, 803
 - anti-sialyl Le^x antibody 804
 - enhanced expression of sialyl Le^x and sialyl Le^a in malignant cells 816
 - expression in cancer 816, 823–824
 - α-O-linked sialyl *Lewis*^x 188
 - sialyl Le^a / sialyl Le^x, terminal structures 812
 - 6-sulfo sLe^x (*see there*) 23, 41, 44–46, 52, 67, 88, 181
 - (2→8)-linked sialyl dimer 73
 - (2→9)-linked derivative 73
 - 2-thiocresol sialyl 68
- sialylation
 - DMTST-promoted 63
 - Q-sialylation 60–72
- sialylparagloboside (SPC) 40
- sialyltransferase (SiaT) 84–90, 150, 818–820
 - from *Neisseria gonorrhoeae* 86
 - α(2→3)-sialyltransferase 186, 647
 - α(2→6)-sialyltransferase 84, 87, 641–646
 - α(2→8)-sialyltransferase 84, 647
 - SiaT isoenzymes 818–819
- siglec ligands 46–50
 - gangliosides (*see there*) 47–49
- silica, amino-bonded 528
- silver silicate (insoluble Ag salt) 261
- silyl ethers 108–109
- single-glycoform proteins 182
- SnCl₂-mediated coupling 229
- solid-phase synthesis 174
- SPC (sialylparagloboside) 40
- sphingoglycolipid 133
- spiramycin 694
- statistical effect 577
- stereoelectronic effects 306–309
- steric 1,3-diaxial-like interactions 320, 323
- STn(c)-MBS-KLH 386
- streptomycin 694
- sucralfate (carafate[®]) 429

- sucrose synthase 142
 - sugar
 - branched-chain sugars, biosynthesis of 730–733
 - deoxysugars, biosynthesis of 714–725
 - 2,6-dideoxy-L-sugar 225
 - enzymatic mechanism in the biosynthesis of unusual sugars 713–741
 - GC-MS sugar analysis 571
 - glycosyltransferases/glycotransferase inhibitors
 - NDP-sugar donors 610–640
 - NMP-sugar donors 641–648
 - isolation of sugar ring fragments from neomycin 494
 - nucleotides 139
 - regeneration 139
 - sugar as a new tool for development of therapeutic agents 863–872
 - sugar-1-phosphate thymidyltransferase 917
 - sulfated
 - chitins 427
 - gangliosides 50
 - molecules, fully synthetic 428–430
 - sulfation, biology of 781–783
 - 4-sulfo-GalB3O 774
 - 4-sulfo-Gal¹⁸Cer 774
 - sulfogalactosyl ceramide 772–775
 - 3-sulfogalactosylglycerolipid 772
 - sulfo-Le^a sequences 753
 - sulfo-Le^x 23, 41, 44–46, 67, 753
 - 6-sulfo sLe^x (6-sulfo sialyl Lewis^x) 23, 41, 44–46, 67, 753, 807, 811–812, 820
 - 6-sulfo cyclic sLe^x 45
 - 6-sulfo de-N-acetyl sLe^x 46
 - sequences 753
 - synthesis 56–59
 - sulfonated molecules 428
 - sulfonates
 - N-sulfonates 451
 - trifluoromethanesulfonate, dimethyl(methylthio)sulfonium (*see* DMTST) 62–63
 - sulfotransferases 820–821
 - biology of sulfation 781–783
 - bisubstrate analogue approach to EST inhibition 788–789
 - cancer therapy 820–821
 - discovery of EST inhibitors from a library of PAP analogues 789–790
 - Golgi-resident (GST) 792–794
 - inhibition of EST by dietary agents and environmental toxins 791–792
 - inhibitors of EST targeted toward the PAPS binding site 784–786
 - small molecule inhibitors of 781–796
 - tyrosyl-protein sulfotransferase-1 (TPST-1) 89
 - sulfur-directed glycosidation 224
 - superbeads 154
 - superbug, Wang's 157–160
 - surface plasmon resonance 132, 368
 - swainsonine 300
 - syn*-pentane interactions 314
- t**
- T antigen 179, 186, 204
 - T cell 206–209
 - epitopes 383
 - CD4⁺ 396
 - helper T cell 206
 - receptor 207
 - T lymphocytes by ManProp 869
 - T₁ value 28
 - T₄ β-glucosyltransferases 614
 - Tat-TAR 666
 - TDP-[4-³H]-6-deoxy-D-glucose 716
 - TDP-2,6-dideoxy-D-glycero-D-galacto-4-hexulose 721
 - TDP-4-keto-6-deoxyglucose 720
 - TDP-D-glucose 4,6-dehydratase 715
 - teicoplanin 909
 - TeNT H_c 51
 - TentaGel 30, 107
 - TGF-β 809
 - thermodynamic models of multivalency effect 541–573
 - 3-thio auxiliaries 74–77
 - 2-thiocresol sialyl 68
 - thioesters, glycopeptide 199
 - thioglycosides 6, 115–117, 218, 233
 - linkers 110
 - 2-thiophenyl glycosides 67
 - thiosialosides 93
 - D-*threo*-1-deoxy-1-morpholinoceramide 612
 - thrombin 442
 - inhibition 452–455
 - domains (*see there*) 452–454
 - thrombocytopenia, heparin-induced (HIT) 441
 - thromboembolism, venous (VTE) 441
 - thymidyltransferase, sugar-1-phosphate 917
 - TIPSoTf 227, 243
 - TMSOTf 235, 237
 - TNF-α 341, 347, 352
 - TOCSY 532

TPST (tyrosyl-protein sulfotransferase) 89, 793–794
 – TPST-1 89
 – TPST-2 793–794
 transaminase 725
 – biosynthesis of mycaminose 729–730
 transglycosylase/transglycosylation 907
 – glycosidase-catalyzed 137
 – monofunctional 907
 trichloroacetimidate 121, 234, 265
 – glycosyl 3, 114–115, 121
 trichloroacetimidate-mediated glycosidation 218
 trisaccharide
 – C-trisaccharide 324–325, 336
 – human blood group trisaccharides 334–336
 – P^k-trisaccharide ligands 557–561
 triterpenoid glycoside 707
 tumor (*see also* cancer)
 – angiogenesis 808–809
 – – roles of humoral factors and cell adhesion molecules in 809
 – immunotargeting of tumor cells expressing unnatural polysialic acids 868–869
 – metastases (*see there*) 803–824
 tunicamycin 288
 turn-like structure 201
 TylC3 733
 tyrosine sulfation 511
 tyrosyl-protein sulfotransferase (*see* TPST) 89, 793–794
 tyvelose 735
 – CDP-tyvelose 2-epimerase 735–737

u

UDP-2-F-GAL 639
 UDP-3-O-acetyl-GlcNAc deacetylase (LpxC) 901
 UDP-6-deoxy-6-fluorogalactose 618
 UDP-D-galactose 4-epimerase 716
 UDP-Gal 4'-epimerase 141
 UDP-galactopyranose mutase 738
 UDP-Galf 739
 UDP-GalNAc 4'epimerase 141
 UDP-Galp 739
 – mutase 739
 UDP-Glc 6'-dehydrogenase 141

UDP-Glc pyrophosphorylase 142
 UDP-GlcNAc
 – pyrophosphorylase 142
 – regeneration 145–146
 UDP-GlcNAc 4-epimerase 147
 UDP-glucuronic acid 633
 UDP-L-fucose 619
 UDP-mannose 619
 UDP-N-acetylglucosamine 2-epimerase 734
 UDP-Xyl 144

v

vaccines
 – cancer vaccines 382–397
 – carbohydrate-based (*see there*) 381–403
 – meningococcal (*see there*) 358–371
 vancomycin 695, 909, 911–912
 – chlorobiphenyl vancomycin 912
 vancosamine 697
 – *epi*-vancosamine 912
 vascular endothelial growth factor (VEGF) 814
 venous thromboembolism (VTE) 441
 VGEF (vascular endothelial growth factor) 814

vicinal coupling 310
 viral coat protein 416
 VT-Gb₃Cer 764
 VT₁-Gb₃Cer 764–765
 VT₁-Gb₃P^k 766
 VT₂-Ada-Gb₃Cer 769

w

Wang's superbug 157–160
 water-soluble
 – polymers 136
 – primers 131

x

2-xanthates, as glycosyl donors 69–71
 xylosides 884–885

y

yersinirose A 731

z

[Zn(OTf)₂/EtSH] 242

